Theremia

Based in France, Theremia develops advanced precision medicine solutions focused on central nervous system diseases, particularly mental health. Their innovative machine learning technology enhances patient-specific treatment strategies. Theremia, founded in 2024, is headquartered in Paris, France. The company specializes in precision medicine solutions targeting CNS diseases.

Theremia raised EUR 3 million in Seed funding on November 7, 2024, co-led by Eurazeo and Salica Investments, with participation from Entrepreneur First and Bpifrance. This funding reflects the company's commitment to enhance knowledge in personalized treatment. Theremia specializes in precision medicine solutions aimed at addressing central nervous system (CNS) diseases, particularly focusing on mental health disorders such as major depressive disorders. The company utilizes advanced machine learning models to analyze extensive health data, enabling a nuanced understanding of patient-specific drug responses based on factors such as gender, age, and ethnicity.

Theremia collaborates closely with biotech companies to integrate these insights at every stage of treatment development, enhancing the precision of drug prescribing and treatment customization. Their services include the development of tools for early diagnosis, patient monitoring solutions, and prevention programs tailored to diverse demographic groups. Theremia’s products and services are offered in various international markets, specifically targeting regions with heightened mental health concerns, including Europe and North America. The revenue structure of Theremia primarily revolves around partnerships with biotech companies and healthcare providers, leveraging a business-to-business (B2B) model.

Transactions generally occur through collaborative agreements that encompass subscription-based access to their analytical platforms and tools, which facilitate the integration of real-world evidence into treatment strategies. Clients typically consist of healthcare institutions and pharmaceutical companies, which utilize Theremia's services to develop tailored therapeutic approaches and improve patient adherence to treatments. The company's flagship offerings are designed to enhance the efficacy of CNS treatments while addressing the critical issue of adverse drug reactions. Pricing structures are established based on the complexity of the services rendered and the specific needs of each partnership, ensuring a tailored approach to client demands.

In November 2024, Theremia raised EUR 3 million in Seed funding to expand its scientific team, develop partnerships, and enhance its personalized treatment platform across Europe. The company plans to launch new products aimed at improving mental health treatment, although specific release dates have not been disclosed. Theremia is targeting expansion into broader European markets, capitalizing on increased demand for mental health solutions.